Author(s):
Sonika, Umesh Dhamodhiran, Aiyushi Das, Buddekallu Veeran Gouda, Kirankumar Rangappa, Rama Bukka, Rama Radhakrishna Nargund, Shravan Laxmivenkatesh Nargund, Shachindra Laxmivenkatesh Nargund, Vemula Kusum Devi, Vijaya Gopalachar Joshi, Malviya Nidhi
Email(s):
vijay.joshi67@gmail.com , nidhi.malviya7@gmail.com
DOI:
10.52711/2231-5659.2026.00053 
Address:
Sonika1, Umesh Dhamodhiran2, Aiyushi Das2, Buddekallu Veeran Gouda2, Kirankumar Rangappa3, Rama Bukka2, Rama Radhakrishna Nargund4, Shravan Laxmivenkatesh Nargund5, Shachindra Laxmivenkatesh Nargund5, Vemula Kusum Devi6, Vijaya Gopalachar Joshi7, Malviya Nidhi2
1Nargund College of Pharmacy, Bangalore, Karnataka, India.
2Department of Pharmaceutics, Nargund College of Pharmacy, Bangalore, Karnataka, India.
3Master of Pharmacy, Department of Pharmaceutics, Nargund College of Pharmacy, Bangalore, Karnataka, India.
4Department of Pharmacology, Nargund College of Pharmacy, Bangalore, Karnataka, India.
5Department of Pharmaceutical Chemistry, Nargund College of Pharmacy, Bangalore, Karnataka, India.
6Department of Pharmaceutics, Nitte College of Pharmaceutical Sciences, Bangalore (Deemed to be University), Bengaluru, Karnataka, India.
7Department of Pharmaceutics, Govt College of Pharmacy, Bangalore, Karnataka, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
Diclofenac sodium is a widely used nonsteroidal anti-inflammatory drug (NSAID) for relieving pain, inflammation, and improving function in conditions such as arthritis, musculoskeletal disorders, postoperative pain, and dysmenorrhea. Its action is mainly due to non-selective inhibition of COX-1 and COX-2 enzymes, reducing prostaglandin synthesis; however, COX-1 inhibition contributes to gastrointestinal, renal, and cardiovascular adverse effects. Although rapidly absorbed, diclofenac undergoes extensive first-pass metabolism, leading to variable bioavailability and inconsistent therapeutic outcomes. These limitations have prompted the development of alternative dosage forms and advanced delivery systems. This review highlights pharmacological properties, therapeutic uses, safety concerns, and evolving formulations of diclofenac sodium. It also discusses innovative carriers such as liposomes, niosomes, bilosomes, transfersomes, nanoparticles, microneedles, and transdermal systems designed to enhance bioavailability, enable controlled release, and reduce toxicity. Various administration routes are evaluated for their benefits and limitations. Overall, advancements in nanotechnology, targeted delivery, and personalized medicine are expected to improve the safety, efficacy, and clinical utility of diclofenac sodium.
Cite this article:
Sonika, Umesh Dhamodhiran, Aiyushi Das, Buddekallu Veeran Gouda, Kirankumar Rangappa, Rama Bukka, Rama Radhakrishna Nargund, Shravan Laxmivenkatesh Nargund, Shachindra Laxmivenkatesh Nargund, Vemula Kusum Devi, Vijaya Gopalachar Joshi, Malviya Nidhi. Emerging Nanocarriers and Advanced Delivery Platforms for Diclofenac: A Comprehensive Review. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(4):364-0. doi: 10.52711/2231-5659.2026.00053
Cite(Electronic):
Sonika, Umesh Dhamodhiran, Aiyushi Das, Buddekallu Veeran Gouda, Kirankumar Rangappa, Rama Bukka, Rama Radhakrishna Nargund, Shravan Laxmivenkatesh Nargund, Shachindra Laxmivenkatesh Nargund, Vemula Kusum Devi, Vijaya Gopalachar Joshi, Malviya Nidhi. Emerging Nanocarriers and Advanced Delivery Platforms for Diclofenac: A Comprehensive Review. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(4):364-0. doi: 10.52711/2231-5659.2026.00053 Available on: https://www.ajpsonline.com/AbstractView.aspx?PID=2026-16-4-6
14. REFERENCES:
1. Vane JR, Botting RM. Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs. Am J Med. 1998; 104(3): 2S-8S. doi:10.1016/S0002-9343(97)00203-9
2. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010; 26(7): 1715-1731. doi:10.1185/03007995.2010.486301
3. Davies NM, Anderson KE. Clinical Pharmacokinetics of Diclofenac: Therapeutic Insights and Pitfalls. Clin Pharmacokinet. 1997; 33(3): 184-213. doi:10.2165/00003088-199733030-00003
4. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci. 1999; 96(13): 7563-7568. doi:10.1073/pnas.96.13.7563
5. Suri A, Chapel S, Lu C, Venkatakrishnan K. Physiologically based and population PK modeling in optimizing drug development: A predict–learn–confirm analysis. Clin Pharmacol Ther. 2015; 98(3): 336-344. doi:10.1002/cpt.155
6. FitzGerald GA, Patrono C. The Coxibs, Selective Inhibitors of Cyclooxygenase-2. Wood AJJ, ed. N Engl J Med. 2001; 345(6): 433-442. doi:10.1056/NEJM200108093450607
7. Tudja P, Khan MZI, Meštrovic E, Horvat M, Golja P. Thermal Behaviour of Diclofenac Sodium: Decomposition and Melting Characteristics. Chem Pharm Bull (Tokyo). 2001; 49(10): 1245-1250. doi:10.1248/cpb.49.1245
8. Viegas A, Manso J, Corvo MC, Marques MMB, Cabrita EJ. Binding of Ibuprofen, Ketorolac, and Diclofenac to COX-1 and COX-2 Studied by Saturation Transfer Difference NMR. J Med Chem. 2011; 54(24): 8555-8562. doi:10.1021/jm201090k
9. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. The Lancet. 2009; 374(9699): 1449-1461. doi:10.1016/S0140-6736(09)60938-7
10. Atzeni F, Masala IF, Sarzi-Puttini P. A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. Pain Ther. 2018; 7(2): 163-177. doi:10.1007/s40122-018-0100-2
11. Caldwell JR. Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis. Semin Arthritis Rheum. 1985; 15(2): 73-79. doi:10.1016/S0049-0172(85)80015-9
12. Chaitanya NSK, Karunakar P, Garlapati K, Yeladandi M, Bidari P, Soni P. A comparative evaluation of diclofenac sodium transdermal patch, oral diclofenac sodium with intramuscular injections of diclofenac sodium in patients suffering from oral pain: A randomized control trial. Int J Pharm Investig. 2017; 7(3): 132. doi:10.4103/jphi.JPHI_52_17
13. Basha KS, Nafees SS, Nethravani G, Naik SBT. Formulation and Evaluation of Diclofenac Suspension by Using Natural Suspending Agents. Res J Pharm Dos Forms Technol. 2016; 8(2): 119. doi:10.5958/0975-4377.2016.00015.X
14. Manian M, Jain P, Vora D, Banga AK. Formulation and Evaluation of the In Vitro Performance of Topical Dermatological Products Containing Diclofenac Sodium. Pharmaceutics. 2022; 14(9): 1892. doi:10.3390/pharmaceutics14091892
15. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: An illustrated review. J Controlled Release. 2014; 185: 22-36. doi:10.1016/j.jconrel.2014.04.015
16. Akbari J, Saeedi M, Morteza-Semnani K, et al. Innovative topical niosomal gel formulation containing diclofenac sodium (niofenac). J Drug Target. 2022; 30(1): 108-117. doi:10.1080/ 1061186X.2021.1941060
17. Singh V, Devi M, Kumar Verma K. A Review article on Diclofenac Sodium Topical gel on Osteoarthritis. Res J Top Cosmet Sci. Published online June 7, 2024: 53-59. doi:10.52711/ 2321-5844.2024.00010
18. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int J Pharm. 2007; 332(1-2): 1-16. doi:10.1016/ j.ijpharm.2006.12.005
19. Bertuola M, Miñán A, Grillo CA, Cortizo MC, Fernández Lorenzo De Mele MA. Corrosion protection of AZ31 alloy and constrained bacterial adhesion mediated by a polymeric coating obtained from a phytocompound. Colloids Surf B Biointerfaces. 2018; 172: 187-196. doi:10.1016/j.colsurfb.2018.08.025
20. Arora D, Nanda S. Quality by design driven development of resveratrol loaded ethosomal hydrogel for improved dermatological benefits via enhanced skin permeation and retention. Int J Pharm. 2019; 567: 118448. doi:10.1016/ j.ijpharm.2019.118448
21. Zarenezhad E, Marzi M, Abdulabbas HT, et al. Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges. J Funct Biomater. 2023; 14(9): 453. doi:10.3390/jfb14090453
22. Hadgraft J, Lane ME. Skin permeation: The years of enlightenment. Int J Pharm. 2005; 305(1-2): 2-12. doi:10.1016/ j.ijpharm.2005.07.014
23. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012; 64: 128-137. doi:10.1016/j.addr.2012.09.032
24. Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A Promising Nanoencapsulation Technique for Transdermal Drug Delivery. Pharmaceutics. 2020; 12(9): 855. doi:10.3390/ pharmaceutics12090855
25. Ita K. Transdermal Delivery of Drugs with Microneedles—Potential and Challenges. Pharmaceutics. 2015; 7(3): 90-105. doi:10.3390/pharmaceutics7030090
26. Hughey JR, Keen JM, Miller DA, Brough C, McGinity JW. Preparation and characterization of fusion processed solid dispersions containing a viscous thermally labile polymeric carrier. Int J Pharm. 2012; 438(1-2): 11-19. doi:10.1016/ j.ijpharm.2012.08.032
27. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Controlled Release. 2004; 100(1): 5-28. doi:10.1016/ j.jconrel.2004.08.010
28. Soujanya B, Priya GP, Murthy TEGK. Studies on Influence of Coprocessed Excipients on Flow and Dissolution Kinetics of Diclofenac Sodium. Res J Pharm Dos Forms Technol. 2015; 7(1): 51. doi:10.5958/0975-4377.2015.00008.7
29. Wakade AB, Waghmode ST, Wagh OA, Gosavi UM. A Review Article on Effervescent Tablet of Diclofenac Sodium. Res J Sci Technol. Published online March 21, 2025: 89-98. doi:10.52711/ 2349-2988.2025.00013
30. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: Current perspectives. J Controlled Release. 2009; 134(2): 74-80. doi:10.1016/j.jconrel.2008.11.011
31. Mudie DM, Amidon GL, Amidon GE. Physiological Parameters for Oral Delivery and in Vitro Testing. Mol Pharm. 2010; 7(5): 1388-1405. doi:10.1021/mp100149j
32. Kondo K, Takeda M, Ejima W, et al. Study of a novel glycoconjugate, thiopeptidoglycan, and a novel polysaccharide lyase, thiopeptidoglycan lyase. Int J Biol Macromol. 2011; 48(2): 256-262. doi:10.1016/j.ijbiomac.2010.11.009
33. Siepmann J, Peppas NA. Higuchi equation: Derivation, applications, use and misuse. Int J Pharm. 2011; 418(1): 6-12. doi:10.1016/j.ijpharm.2011.03.051
34. Bertens CJF, Zhang S, Erckens RJ, et al. Confocal Raman spectroscopy: Evaluation of a non-invasive technique for the detection of topically applied ketorolac tromethamine in vitro and in vivo. Int J Pharm. 2019; 570: 118641. doi:10.1016/ j.ijpharm.2019.118641
35. Hiorth M, Skøien T, Sande SA. Immersion coating of pellet cores consisting of chitosan and calcium intended for colon drug delivery. Eur J Pharm Biopharm. 2010; 75(2): 245-253. doi:10.1016/j.ejpb.2010.02.012
36. Mehnert W. Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3): 165-196. doi:10.1016/S0169-409X(01)00105-3
37. Hasan N, Imran M, Kesharwani P, et al. Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Int J Pharm. 2021; 599: 120428. doi:10.1016/ j.ijpharm.2021.120428
38. Franz TJ. Percutaneous Absorption. On the Relevance of in Vitro Data. J Invest Dermatol. 1975; 64(3): 190-195. doi:10.1111/1523-1747.ep12533356
39. Sudhakar P, Pushkalai SP, Sabarinath C, Priyadharshini S, Haripriya S. Molecular docking and synthesis of 1, 2, 4 -triazin analogue of diclofenac as potential ligand for parkinson’s. Res J Pharmacol Pharmacodyn. 2018; 10(1): 8. doi:10.5958/2321-5836.2018.00002.2
40. Rahmani S, Zaaeri F, Javar HA. Optimization of Drug loading in Modified Nano-zeolites using response surface Methodology by Box-Behnken Design. Asian J Pharm Res. 2020; 10(2): 55. doi:10.5958/2231-5691.2020.00011.8
41. A. Yeola C, N. Sonawane V, N. Sonawane V, R. Surana K, M. Patil D, D. Sonawane D. Development and Validation of Simple UV- Spectrophotometric Method for Estimation of Diclofenac Sodium. Asian J Pharm Anal. Published online September 7, 2023: 183-189. doi:10.52711/2231-5675.2023.00030
42. Remi SL, Varkey J, Maheshwari RK, Nair AJ. A novel ecofriendly, cost effective mobile phase for hplc- simultaneous estimation and validation of paracetamol and diclofenac sodium in bulk and pharmaceutical formulation by rp-hplc using hydrotropic solution as mobile phase. Asian J Pharm Res. 2020; 10(3): 163. doi:10.5958/2231-5691.2020.00029.5
43. Brune, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. Published online February 2015: 105. doi:10.2147/JPR.S75160
44. Kumaresan C. Thumb arthritis treatment with diclofenac sodium Gel Formulation. Asian J Res Pharm Sci. 2020; 10(4): 239-240. doi:10.5958/2231-5659.2020.00043.0
45. Inayathulla, Goudanavar P, Acharya A. Development and Evaluation of In-situ gel containing Linezolid and Diclofenac Sodium in the treatment of Periodontitis. Asian J Pharm Technol. 2020; 10(1): 20. doi:10.5958/2231-5713.2020.00005.7